Long-term antibody-response monitoring following primary exposure to SARS-COV-2 and afterward mRNA COVID-19 vaccination: A case report

Bela Balint; Milena Todorović Balint; Zorana  Andrić; Milica  Jovičić; Glorija  Blagojević; Miodrag  Čolić

doi:10.2298/VSP200220019B

Bela Balint Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia
Milena Todorović Balint University Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia
Zorana Andrić Blood Transfusion Institute of Serbia, Belgrade, Serbia
Milica Jovičić Blood Transfusion Institute of Serbia, Belgrade, Serbia
Glorija Blagojević Blood Transfusion Institute of Serbia, Belgrade, Serbia
Miodrag Čolić Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP200220019B

Keywords: antibodies, covid-19, covid-19 serotherapy, infections, vaccination

References

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Throm-bosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383(2): 120–8.

Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 2020; 9: e59177.

Khalaf K, Papp N, Chou JT, Hana D, Mackiewicz A, Kaczmarek M. SARS-CoV-2: Pathogenesis, and advancements in diagnos-tics and treatment. Front Immunol 2020; 11: 570927.

Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: A review. Front Med (Lausanne) 2020; 7: 480.

Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 2020; 12(1): 1854149.

Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370(6521): 1227–30.

Yin S, Tong X, Huang A, Shen H, Li Y, Liu Y, et al. Longitudi-nal anti-SARS-CoV-2 antibody profile and neutralization ac-tivity of a COVID-19 patient. J Infect 2020; 81(3): e31–e32.

Xu TM, Lin B, Chen C, Liu LG, Xue Y. Non-optimal effec-tiveness of convalescent plasma transfusion and hydroxychlo-roquine in treating COVID-19: a case report. Virol J 2020; 17(1): 80.

Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The effi-cacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther 2020; 5(1): 219.

Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol 2021; 222: 108634.

Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 2021; 17(1): 8–19.

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063.